Roche Announces FDA Approval of Adjuvant Tecentriq for Stage III dMMR Colon Cancer
Published in Diseases!, Drugs development & discovery, Immunology.
Publication date: October 9, 2026.
Roche announced U.S. FDA approval of Tecentriq and Tecentriq Hybreza, each combined with a fluoropyrimidine and oxaliplatin, for adjuvant treatment of stage III colon cancer with deficient DNA mismatch repair (dMMR). Adjuvant therapy is given after surgery to reduce recurrence risk.
The decision is supported by ATOMIC, a randomized, open-label Phase 3 study enrolling 712 patients. Participants received modified FOLFOX6 chemotherapy with or without atezolizumab, the PD-L1-targeting antibody in Tecentriq. The combination arm continued atezolizumab after its initial six months of chemotherapy.
Roche reported three-year disease-free survival of 86% with the combination versus 76% with chemotherapy alone. The reported 50% reduction in the risk of recurrence or death is a relative time-to-event measure; it is not a 50-percentage-point increase in survival or a guarantee of cure.
The announcement concerns a specific molecular subtype and a U.S. regulatory decision. It does not establish Canadian approval for this indication. Roche reported safety consistent with earlier studies; immunotherapy can also affect normal tissues, so the treatment’s benefits and risks require clinical assessment.
Source: Roche announcement and ATOMIC study summary, October 9, 2026.